These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35379118)

  • 1.
    Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
    Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
    Wang Z; Xing L; Huang Y; Han P
    Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
    Zhu C; Du Y; Huai Q; Fang N; Xu W; Yang J; Li X; Zhang Y; Zhang X; Dai H; Li X; Wang H; Dai Y
    Reprod Sci; 2024 Feb; 31(2):532-549. PubMed ID: 37798609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
    Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
    J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
    Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
    World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
    Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
    Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
    Lu X; Jing L; Liu S; Wang H; Chen B
    Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
    Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
    J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
    Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
    Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
    He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
    J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma.
    Jiang N; Li D; Han Y; Luo ZG; Liu LB
    Aging (Albany NY); 2024 Jun; 16(11):9784-9812. PubMed ID: 38848146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance analysis of PAX8 expression in endometrial carcinoma.
    Hu S; Gan H; Yang F
    Medicine (Baltimore); 2022 Oct; 101(42):e31159. PubMed ID: 36281161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL9 correlates with antitumor immunity and is predictive of a favorable prognosis in uterine corpus endometrial carcinoma.
    Xue S; Su XM; Ke LN; Huang YG
    Front Oncol; 2023; 13():1077780. PubMed ID: 36845675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of ESRRA in Endometrial Cancer.
    Wang S; Huo X
    Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma.
    Wang G; Fu J; Liu M; Zheng Q
    PLoS One; 2024; 19(1):e0277872. PubMed ID: 38232115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.